TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05269316: Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

Sponsor: Impact Therapeutics, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 61 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,492,260

Rescue Site Savings

+$981,750

Unlock Full NCT05269316 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05269316 Rescue Dossier →